Strategic partnerships Oakwood Labs specializes in long acting injectable LAI development and has experience from feasibility through commercial supply, presenting a robust outsourcing partner for pharma companies seeking end-to-end LAI programs.

Manufacturing capacity With aseptic GMP manufacturing for clinical and commercial products and in-house QC chemistry and microbiology, Oakwood can support scale-up and ensure quality control across stages, appealing to sponsors requiring reliable production capabilities.

Technology edge Sustained release microsphere technology enables tailored release profiles, offering a selling point for customers aiming to optimize dosing, patient adherence, and competitive differentiation in LAI products.

Financial footprint Reported revenue range of 50 to 100 million positions Oakwood as a mid-sized partner with potentially flexible pricing, capacity for medium to large LAI programs, and opportunities for multi-project collaborations.

Market signals Past partnerships with Edge Therapeutics for commercial manufacturing and ongoing demand in LAI development indicate strong market demand for Oakwood’s end-to-end services, suggesting opportunities with mid-to-large biotech and specialty pharma players seeking LAI manufacturing and development expertise.